Chart of the Week: Panels Emerging, Single Biomarker Tests Dominate


For the chart of the week we wanted to explore the market for multi-analyte panels.  We found that single biomarker tests still vastly outnumber panels.  Stay tuned for more trending information in the coming weeks.  My hypothesis: Panels, even outside of NGS, are being introduced to the market faster than single biomarker tests.


Share this Image On Your Site

<p><strong>Please include attribution to with this graphic.</strong><br /><br /><a href=’’><img src=’’ alt=’Biomarker Counts in Diagnostic Tests’ width=’540px’ border=’0′ /></a></p>

For a refresher on Amplion and BiomarkerBase:



Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access